R Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO
Emory & Henry College
H-index: 48
North America-United States
Top articles of R Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors | Clinical Therapeutics | Gerald Falchook Amita Patnaik Debra L Richardson R Donald Harvey Manish R Sharma | 2024/2/28 |
Mymel: A Phase 1 Trial of AUC-Targeted High Dose Melphalan in Multiple Myeloma Patients Undergoing Autologous Transplant | Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy | Karen Sweiss Kyeongmin Kim Janet Guo Kasey Hill Nicole Abbott | 2024/2/1 |
Interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma. | Jacqueline T Brown Bassel Nazha Yuan Liu Shreya Ranbhise Kelsea Lozada | 2024/2/1 | |
Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies | Clinical Cancer Research | Benedito A Carneiro Ludimila Cavalcante Devalingam Mahalingam Anwaar Saeed Howard Safran | 2024/2/1 |
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors | Cancer Medicine | Dejan Juric Minal Barve Ulka Vaishampayan Desamparados Roda Aitana Calvo | 2024/3 |
A call to action to advance patient‐focused and decentralized clinical trials | Cancer | R Donald Harvey Therica M Miller Patricia A Hurley Ramya Thota Lora J Black | 2024/1/9 |
372 TABLET: food effect study of niraparib tablets in patients with advanced solid tumours | Debra L Richardson Gerald Falchook R Donald Harvey Manish Sharma Navid Hafez | 2024/3/1 | |
TABLET: Relative bioavailability and bioequivalence study of niraparib tablets and capsules in patients with advanced solid tumors. | Gerald Steven Falchook Amita Patnaik Manish Sharma R Donald Harvey Erika P Hamilton | 2023/6/1 | |
Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast | The Oncologist | Chloe S Lalonde Jeffrey M Switchenko Madhusmita Behera Mehmet A Bilen Taofeek K Owonikoko | 2023/12/1 |
Who reconstitutes my chemotherapy? Examining the educational needs of oncology pharmacy practitioners in Nigeria | Cancer Research | Runcie C Chidebe Ramatu M Alabelewe Darlingtina K Esiaka Gloria C Okwu Tochukwu C Orjiakor | 2023/4/4 |
Chemotherapy dosing in older adults with cancer: One size does NOT fit all | Journal of Geriatric Oncology | Grant R Williams Darryl Outlaw R Donald Harvey Stuart M Lichtman William C Zamboni | 2023/1/1 |
A phase 2 evaluation of daratumumab-based induction therapy in patients with multiple myeloma with severe renal insufficiency. | R Donald Harvey Joseph Franz Nisha S Joseph Jonathan L Kaufman Elise Hitron | 2023/6/1 | |
616 Pharmacokinetics and safety of a subcutaneous formulation of nivolumab (NIVO SC) monotherapy: updated results from the phase 1/2 CheckMate 8KX study | Sara Lonardi Iwona Ługowska Anne O’Donnell Christopher Jackson Loes Maria Latten-Jansen | 2023/11/1 | |
MP12-03 IMPLICATIONS OF RACE FREE RENAL FUNCTION EQUATIONS ON BLACK PATIENTS WITH RENAL CELL CARCINOMA | The Journal of Urology | Benjamin N Schmeusser Arnold R Palacios Eric Midenberg Reza Nabavizadeh Adil Ali | 2023/4 |
First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors. | Gerald Steven Falchook Yan Liang R Donald Harvey Siqing Fu Yao Weitao | 2023/6/1 | |
Impact of black race on peripheral neuropathy in patients with newly diagnosed multiple myeloma receiving bortezomib induction | JCO Oncology Practice | Laura F Sun Kathryn T Maples Kevin H Hall Yuan Liu Yichun Cao | 2023/9 |
Race‐free renal function estimation equations and potential impact on Black patients: Implications for cancer clinical trial enrollment | Cancer | Benjamin N Schmeusser Arnold R Palacios Eric R Midenberg Reza Nabavizadeh Dattatraya H Patil | 2023/3/15 |
EZH2/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: Preliminary phase II results. | Charles Drescher Harriet S Walter Thomas Gastinne Nehal J Lakhani Vincent Ribrag | 2023/6/1 | |
Debunking sex and disentangling gender from oncology | Journal of clinical oncology: official journal of the American Society of Clinical Oncology | Ash B Alpert Lexis Rivers Charlie Manzano Roman Ruddick Spencer Adams | 2023/8/1 |
Effect of race-free estimated glomerular filtration rate equations (eGFR) on oncology clinical trial eligibility for Black patients. | Benjamin Schmeusser Arnold Raul Palacios Eric Midenberg Reza Nabavizadeh Dattatraya H Patil | 2023/2/20 |
